Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: Significance of expression of the multidrug resistance gene-1 (MDR1)

Leukemia

Volumn 10, Issue SUPPL. 1, 1996, Pages

  Willman, Cheryl L ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

AML; Cytogenetics; Elderly; Immunophenotype; Leukemia; MDR1

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOGENETICS; GENE EXPRESSION; HUMAN; IMMUNOPHENOTYPING; LYMPHOBLAST; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0029868137     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MD41) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant CD34+/MDR-/efflux+ and MDR1 +/efflux- cases. Blood 1995; 86: 2329-2342.
2. Leith CP, Kopecky KJ, Chen IM. MDR1 expression is highly predictive for achievement of complete remission (CR) in acute myeloid leukemia (AML) in the elderly: a Southwest Oncology Group study. Submitted to Blood.
3. Leith CP, Kopecky KJ, Chen IM, et al. Multidrug resistance (MDR1) expression and function in acute leukemia in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR). Leukemia 1995; 9: 535 (abstract).
4. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9: 3808-3820.
5. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993; 60: 157-180.
6. Arceci RJ. Clinical significance of p-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215-2222.
7. Nooter K, Sonneveld P. Clinical relevance of p-glycoprotein expression in haematological malignancies. Leukemia Res 1994; 18: 233-243.
8. List AF. Multidrug resistance: clinical relevance in acute leukemia. Oncology 1993; 7: 23-28.
9. Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA, Preisler HD. Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 1990; 14: 11-21.
10. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991; 77: 50-55.
11. Zhou DC, Marie JP, Suberville AM, Zittoun R. Relevance of MDR1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879-885.
12. Willman CL, Kopecky K, Griffith B, Chen IM, Noonan K, Roninson I, Head DR, Tsuruo T, Weick J, Grever M, Appelbaum F. Multiparameter analysis of the expression of the multidrug resistance genes MDR1 and MDR2 (MDR3) in de novo AML by polymerase chain reaction in multicolor flow cytometry: identification of a biological subset of CD-34+ MDR1 + AML cases. Blood 1991; 78: 172a (abstract).
13. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
14. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
15. Sonneveld P, van Dongen JJM, Hagemeijer A, van Lorn K, Nooter K, Schoester M, Adriaansen HJ, Tsuruo T, de Leeuw K. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 1993; 7: 963-969.
16. List AF, Spier CM, Cline A, Doll DC, Garewal H, Morgan R, Sandberg AA. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991; 78: 28-34.
17. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994; 8: 388-394.
18. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, Civin CI. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem cell glycoprotein CD34 (My10). Br J Haematol 1990; 76: 340-347.
19. Willman CL, Kopecky K, Weick J, Appelbaum F, Grever MR, Head DR, Elias L, Balcerzak SP, Mills GM, Hynes HE. Biologic parameters that predict treatment response in de novo acute myeloid leukemia: CD34, but not multidrug resistant (MDR) gene expression, is associated with a decreased complete remission rate and CD34+ patients more frequently achieved CR with high-dose cytosine arabinoside. Proc ASCO 1992; 11: 262a (abstract).
20. Campos L, Guyotat D, Jaffar C, Solary E, Archimbaud E, Treille D. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Eur J Haematol 1992; 48: 254-258.
21. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-592.
22. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopiner M, Scherrer R, Valent P, Havelec L. MDR1 gene expression and treatment outcome in acute myeloid leukemia. JNCI 1991; 83: 708-712.
23. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute nonlymphocytic leukemia. Eur J Haematol 1992; 48: 87-92.
24. Leith CP, Kopecky KJ, Chen IM, Godwin JE, Appelbaum FR, Head DR, Willman CL. Correlation of functional efflux and multidrug resistance (MDR1) expression in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission. Blood 1994; 84: 377a (abstract).
25. Zochbauer S, Gsur A, Brunner R, Kryle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8: 974-977.
26. Wood P, Burgess R, MacGregor A, Yin JAL. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87: 509-514.
27. Rowley JD, Alimena G, Garson OM, Hagemeijer A, Mitelman F, Prigogina EL. A collaborative study of the relationship of the morphologic type of acute non-lymphocytic leukemia with patient age and karyotype. Blood 1982; 59: 1013-1022.